{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:19:46Z","timestamp":1789600786311,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Japanese encephalitis remains a serious health concern in Asian countries and has sporadically affected pediatric travelers. In the present study, we monitored the safety profile of the Japanese encephalitis virus vaccine IXIARO (Valneva Austria GmbH, Vienna, Austria) in a pediatric population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We randomized 1869 children between 2 months and 17 years of age in an age-stratified manner to vaccination with IXIARO or one of the control vaccines, Prevnar (formerly Wyeth Pharmaceuticals Inc., now Pfizer Inc., Kent, United Kingdom) and HAVRIX 720 (GlaxoSmithKline Biologicals, Rixensart, Belgium). Adverse events (AEs) (unsolicited and solicited local and systemic AEs), serious AEs and medically attended AEs were assessed up to day 56 and month 7 after the first dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Incidences of AEs, serious AEs or medically attended AEs did not differ significantly between the groups in any age stratum. AEs were most frequent in children &lt;1 year of age and decreased with age. AEs of special interest, predefined as AEs associated with potential hypersensitivity\/allergy or neurologic disorders up to day 56, were reported in 4.6% (IXIARO) versus 6.3% (Prevnar) in the \u22652 months to &lt;1 year age group and 3.4% (IXIARO) versus 3.3% (HAVRIX) in the \u22651 to &lt;18 years age group. Fever, the most frequent systemic reaction in 23.7% of infants to 3.8% of adolescents, decreased with age and did not differ between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The safety profile of IXIARO was comparable to the control vaccines in terms of overall AE rates, serious AEs and medically attended AEs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001623","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T16:13:49Z","timestamp":1493136829000},"page":"889-897","source":"Crossref","is-referenced-by-count":17,"title":["Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children"],"prefix":"10.1097","volume":"36","author":[{"given":"Katrin L.","family":"Dubischar","sequence":"first","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kadlecek","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sablan","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa Fay","family":"Borja-Tabora","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvacion","family":"Gatchalian","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Westritschnig","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis.","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(97)07509-0","article-title":"Poliomyelitis-like illness due to Japanese encephalitis virus.","volume":"351","author":"Solomon","year":"1998","journal-title":"Lancet"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review.","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1371\/journal.pntd.0000114","article-title":"Measuring the burden of neglected tropical diseases: the global burden of disease framework.","volume":"1","author":"Mathers","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973-2008.","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2008.062","article-title":"Japanese encephalitis vaccines\u2013needs, flaws and achievements.","volume":"389","author":"Tauber","year":"2008","journal-title":"Biol Chem"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age.","volume":"28","author":"Kaltenb\u00f6ck","year":"2010","journal-title":"Vaccine"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/INF.0000000000001615","article-title":"Immunogenicity of the inactivated Japanese encephalitis virus vaccine IXIARO in children from a Japanese encephalitis virus-endemic region.","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2471\/BLT.07.048025","article-title":"Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data.","volume":"86","author":"Destefano","year":"2008","journal-title":"Bull World Health Organ"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.1.1.9","article-title":"Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use.","volume":"1","author":"Andr\u00e9","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"key":"R16-20230912","first-page":"664","article-title":"Update on Japanese encephalitis vaccine for children\u2014United States.","volume":"60","year":"2011","journal-title":"MMWR"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201709000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:00:24Z","timestamp":1694559624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201709000-00020"}},"subtitle":["An Open-label, Randomized, Active-controlled, Phase 3 Study"],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001623","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}